Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01503944 · ClinicalTrials.gov registry record · Phase 1

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

A Phase 1 study of Parkinson's Disease and Alzheimers Disease, sponsored by Avid Radiopharmaceuticals.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT01503944: Completed Phase 1 study of Parkinson's Disease and Alzheimers Disease, sponsored by Avid Radiopharmaceuticals.

NCT01503944 is a Phase 1 study of Parkinson's Disease and Alzheimers Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 30 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01503944, a Phase 1 study of Parkinson's Disease and Alzheimers Disease, has completed, sponsored by Avid Radiopharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.

Primary Outcome

The ratio of tracer activity in striatal target areas of interest relative to the occipital cortex reference region

Interventions

  • DRUG 18F-AV-133
  • DRUG 18F-AV-45

Study Locations (2)

Arizona

  • Research Site - Sun City

Pennsylvania

  • Research Site - Philadelphia

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-03
Est. Completion 2011-07
Phase Phase 1
Avid Radiopharmaceuticals

42 total trials

What the finished NCT01503944 record still lists

NCT01503944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which 18F-AV-133 is the first listed.

NCT01503944 reports a single indexed study location in Arizona, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01503944 about?

NCT01503944 is a clinical study titled "A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)". The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control s...

What is the current status of trial NCT01503944?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-03. Estimated completion is 2011-07.

What conditions does trial NCT01503944 study?

This clinical trial studies the following conditions: Parkinson's Disease, Alzheimers Disease, Dementia With Lewy Bodies.

What interventions are being tested in trial NCT01503944?

The interventions under investigation include: 18F-AV-133 (DRUG), 18F-AV-45 (DRUG).

Who is sponsoring clinical trial NCT01503944?

This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01503944 being conducted?

This trial has 2 study locations across Arizona, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01503944's enrollment target sits among peer trials

30 108th of 158 higher than 47 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01503944, the US trial registry maintained by the National Library of Medicine. NCT01503944 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.